New research shows that DNA polymerase θ is a key player in PARP-mediated DNA 
damage repair and essential for the survival of cancer cells where homologous 
recombination is compromised. Polθ could be a biomarker for PARP-inhibitor 
response, and is a potential therapeutic target for overcoming resistance to 
these drugs.